The effect of viloxazine (300 mg daily) on the pharmacokinetics of carbamazepine-10,11-epoxide (CBZ-E) the active metabolite of carbamazepine, was investigated in five healthy volunteers. Viloxazine treatment caused a slight but significant prolongation of CBZ-E half-life from 6.7 ± 0.6 to 8.9 ± 1.2 h (Mean values ± S.D. p <0.05), while the other kinetic parameters of CBZ-E were not significantly affected. These preliminary findings suggest that viloxazine inhibits the hepatic metabolism of CBZ-E.
|Translated title of the contribution||Effect of viloxazine on the pharmacokinetics of carbamazepine-10, 11-epoxide|
|Title of host publication||Bollettino - Lega Italiana contro l'Epilessia|
|Number of pages||2|
|Publication status||Published - 1989|
ASJC Scopus subject areas
- Clinical Neurology